2021 APCCC报告:晚期前列腺癌患者的管理

2022-04-18 国外肿瘤科相关专家小组(统称) Eur Urol

晚期前列腺癌在治疗、影像学以及分子特征方面的创新改善了患者的预后,但仍有许多方面的管理缺乏高水平证据指导临床实践。2021年晚期前列腺共识会议(APCCC)解决了其中的一些问题,以补充基于1级证据的指

中文标题:

2021 APCCC报告:晚期前列腺癌患者的管理

英文标题:

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

发布日期:

2022-04-18

简要介绍:

晚期前列腺癌在治疗、影像学以及分子特征方面的创新改善了患者的预后,但仍有许多方面的管理缺乏高水平证据指导临床实践。2021年晚期前列腺共识会议(APCCC)解决了其中的一些问题,以补充基于1级证据的指导建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 APCCC报告:晚期前列腺癌患者的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ae4191c002a19ee0, title=2021 APCCC报告:晚期前列腺癌患者的管理, enTitle=Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021, guiderFrom=Eur Urol, authorId=0, author=, summary=晚期前列腺癌在治疗、影像学以及分子特征方面的创新改善了患者的预后,但仍有许多方面的管理缺乏高水平证据指导临床实践。2021年晚期前列腺共识会议(APCCC)解决了其中的一些问题,以补充基于1级证据的指, cover=https://img.medsci.cn/20220425/1650871270773_1608702.png, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Mon Apr 18 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">晚期前列腺癌在治疗、影像学以及分子特征方面的创新改善了患者的预后,但仍有许多方面的管理缺乏高水平证据指导临床实践。2021年晚期前列腺共识会议(APCCC)解决了其中的一些问题,以补充基于1级证据的指导建议。</span></p>, tagList=[TagDto(tagId=26722, tagName=晚期前列腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=30065, appHits=44, showAppHits=0, pcHits=273, showPcHits=30007, likes=0, shares=4, comments=4, approvalStatus=1, publishedTime=Mon Apr 25 15:20:00 CST 2022, publishedTimeString=2022-04-18, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Mon Apr 25 15:23:03 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 19:21:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 APCCC报告:晚期前列腺癌患者的管理.pdf)])
2021 APCCC报告:晚期前列腺癌患者的管理.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1222577, encodeId=3b8e12225e7b7, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66fa5126061, createdName=14646eb0m88暂无昵称, createdTime=Thu May 26 12:10:29 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214511, encodeId=12981214511ca, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Tue Apr 26 13:46:13 CST 2022, time=2022-04-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1222577, encodeId=3b8e12225e7b7, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66fa5126061, createdName=14646eb0m88暂无昵称, createdTime=Thu May 26 12:10:29 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214511, encodeId=12981214511ca, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Tue Apr 26 13:46:13 CST 2022, time=2022-04-26, status=1, ipAttribution=)]